IRadimed (IRMD) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRadimed in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IRMD shares.
View IRMD analyst ratings or view top-rated stocks.

1 brokerages have issued 12 month price objectives for IRadimed's stock. Their IRMD share price forecasts range from $48.00 to $50.00. On average, they predict the company's share price to reach $49.00 in the next year. This suggests a possible upside of 2.1% from the stock's current price.
View analysts price targets for IRMD or view top-rated stocks among Wall Street analysts.

IRadimed's stock was trading at $28.29 at the start of the year. Since then, IRMD shares have increased by 69.7% and is now trading at $48.00.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our IRMD earnings forecast.

IRadimed Co. (NASDAQ:IRMD) announced its earnings results on Thursday, May, 4th. The medical equipment provider reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. The medical equipment provider earned $15.48 million during the quarter, compared to the consensus estimate of $14.76 million. IRadimed had a net margin of 24.27% and a trailing twelve-month return on equity of 20.03%.

IRadimed announced a dividend on Monday, February 6th. Investors of record on Monday, February 13th will be paid a dividend of $1.05 per share on Tuesday, February 21st. This represents a dividend yield of 2.54%. The ex-dividend date is Friday, February 10th. This is a positive change from the stock's previous dividend of $1.00.
Read our dividend analysis for IRMD.

ETFs with the largest weight of IRadimed (NASDAQ:IRMD) stock in their portfolio include Ballast Small/Mid Cap ETF (MGMT), Janus Henderson Small Cap Growth Alpha ETF (JSML), Royce Quant Small-Cap Quality Value ETF (SQLV),

IRadimed updated its second quarter 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of $0.30-$0.32 for the period, compared to the consensus EPS estimate of $0.30. The company issued revenue guidance of $15.60 million-$15.80 million, compared to the consensus revenue estimate of $15.10 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other IRadimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR).

IRadimed trades on the NASDAQ under the ticker symbol "IRMD."

IRadimed's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.61%), BlackRock Inc. (3.52%), RK Capital Management LLC (2.66%), Bares Capital Management Inc. (2.52%), Russell Investments Group Ltd. (1.69%) and Ranger Investment Management L.P. (1.63%). Insiders that own company stock include Anthony Vuoto, Christopher K Scott, James B Hawkins, Monty K Allen, Monty K Allen and Roger E Susi.
View institutional ownership trends.

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRMD stock can currently be purchased for approximately $48.00.

IRadimed (NASDAQ:IRMD) has a market capitalization of $604.80 million and generates $53.30 million in revenue each year. The medical equipment provider earns $12.83 million in net income (profit) each year or $1.09 on an earnings per share basis.

The company employs 110 workers across the globe.

IRadimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The official website for the company is www.iradimed.com. The medical equipment provider can be reached via phone at (407) 677-8022, via email at investorrelations@iradimed.com, or via fax at 407-677-5037.